WATERTOWN, MA, EnPlusOne Biosciences, harnessing the power of enzymes to synthesize RNA oligonucleotides, launched with $12 million in seed financing.
EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, formally launched with $12 million in seed financing.
The round was led by Northpond Ventures with participation from Breakout Ventures, Coatue, and angel investors. The financing will support continued development and scaling of the company's proprietary ezRNA™ synthesis platform in line with the company's mission to enable next-generation solutions for emerging RNA therapeutics.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
